CapForce Inc.
Close on Oct 19, 2026
- Market cap
- $50.33M
- P/E (TTM)
- 0.7
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q3 FY2023 Ended Sep 30, 2023 | Nov 14, 2023 | During market hours | $700.00K | $-0.46 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 10, 2023 | During market hours | – | – | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 15, 2023 | During market hours | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Jan 18, 2023 | During market hours | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 10, 2022 | During market hours | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Jul 8, 2022 | During market hours | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 12, 2022 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Jan 10, 2022 | During market hours | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 12, 2021 | Before market open | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 12, 2021 | During market hours | – | – | – |
| Q1 FY2021 Ended Mar 31, 2021 | May 13, 2021 | Before market open | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Jan 13, 2021 | During market hours | – | – | – |
Press releases
Announcements CapForce filed with the SEC
Inc. (OTC: OPGN) Announces Name Change to CapForce Inc.
Executive or director change · Charter or bylaw amendment · Shareholder vote results · Regulation FD disclosure · EX-99.1 to Form 8-K
OpGen Announced 1-for-10 Reverse Stock
Material agreement · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
OpGen Provides Update on Business Operations
Material agreement · Other events · EX-99.1 to Form 8-K
OpGen Announces Acquisition of Preferred Stock by David Lazar
Material agreement · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
OpGen Reports Third Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Inducement Transaction for up to $11.2 Million in Gross Proceeds
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
OpGen Reports Second Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
OpGen Reports First Quarter 2023 Financial
Results of operations · EX-99.1 to Form 8-K
Announces Pricing of $3.5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Announces Closing of $3.5 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
Into Distribution Agreement for Unyvero in the U.S. with Fisher Healthcare
Other events · EX-99.1 to Form 8-K
OpGen Submits De Novo request to the U.S. FDA for Unyvero Urinary
Other events · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Results of operations · EX-99.2 to Form 8-K
OpGen Announces Exercise of All Prefunded Warrants
Other events · EX-99.1 to Form 8-K
Provides Preliminary Unaudited Revenue for FY 2022 and Business Update
Results of operations · EX-99.1 to Form 8-K
of $7.5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
of $7.5 Million Public Offering
Material agreement · Other events · EX-99.2 to Form 8-K
OpGen Announced 1-for-20 Reverse Stock Split
Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
OpGen Announces Positive Top Line Data from Clinical Trial for
Other events · EX-99.1 to Form 8-K
OpGen Reports Third Quarter 2022 Financial
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Announces $3.38 Million Registered Direct Offering
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Announces Closing of $3.38 Million Registered Direct Offering
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
OpGen Subsidiary Curetis and FIND Sign R&D
Other events · EX-99.1 to Form 8-K
Grants OpGen 180-Day Extension to Meet Minimum Bid Price Requirement
Listing notice · Other events · EX-99.1 to Form 8-K
OpGen Reports Second Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Announces Preliminary Unaudited Revenue and Cash Position for Second Quarter 2022 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K